Clinical Trials Daily (Page 4)

Metabolic

Altimmune’s Pemvidutide Achieves 59.1% MASH Resolution: A Potent "Defatting" Engine Faces the Fibrosis Lag Challenge

Phase 2b IMPACT trial data confirms best-in-class liver fat reduction, but a missed 24-week fibrosis endpoint necessitates a strategic pivot for Phase 3 design. * These analyses reflect my personal opinions and may include input from multiple sources. They are for informational purposes only and do not constitute professional advice. * What

News

Deramiocel Achieves Statistical Significance in Phase 3 HOPE-3 Trial: 54% Slowing of Skeletal Disease Progression and Critical Cardiac Preservation

Capricor Therapeutics’ pivotal data addresses previous regulatory hurdles, positioning the cell therapy as a first-in-class treatment for Duchenne cardiomyopathy.

News

CervoMed’s Neflamapimod Reduces Plasma GFAP by 16% in DLB, Validating 'Bioavailability Hypothesis' for Phase 3

New biomarker data from the RewinD-LB extension confirms that optimized drug delivery reverses neuroinflammation, reviving the asset's commercial potential against a backdrop of unmet need.

Latest

Altimmune’s Pemvidutide Achieves 59.1% MASH Resolution: A Potent "Defatting" Engine Faces the Fibrosis Lag Challenge

Deramiocel Achieves Statistical Significance in Phase 3 HOPE-3 Trial: 54% Slowing of Skeletal Disease Progression and Critical Cardiac Preservation

CervoMed’s Neflamapimod Reduces Plasma GFAP by 16% in DLB, Validating 'Bioavailability Hypothesis' for Phase 3